X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rosuvastatin (701) 701
humans (597) 597
index medicus (530) 530
pharmacology & pharmacy (462) 462
male (381) 381
rosuvastatin calcium (381) 381
pharmacokinetics (322) 322
statins (307) 307
female (271) 271
atorvastatin (261) 261
middle aged (221) 221
adult (195) 195
drug interactions (188) 188
simvastatin (183) 183
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (182) 182
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (174) 174
pravastatin (171) 171
animals (168) 168
fluorobenzenes - pharmacokinetics (160) 160
pyrimidines - pharmacokinetics (144) 144
sulfonamides - pharmacokinetics (142) 142
aged (138) 138
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (136) 136
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (135) 135
cholesterol (132) 132
antilipemic agents (127) 127
fluorobenzenes - therapeutic use (123) 123
research (122) 122
analysis (117) 117
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (112) 112
pyrimidines - therapeutic use (109) 109
sulfonamides - therapeutic use (108) 108
fluorobenzenes - administration & dosage (97) 97
safety (97) 97
pyrimidines - administration & dosage (92) 92
sulfonamides - administration & dosage (89) 89
dosage and administration (87) 87
treatment outcome (87) 87
area under curve (86) 86
cholesterol, ldl - blood (85) 85
dose-response relationship, drug (85) 85
fluorobenzenes - pharmacology (85) 85
cardiac & cardiovascular systems (84) 84
hypercholesterolemia (82) 82
young adult (81) 81
lipids (80) 80
efficacy (78) 78
hypercholesterolemia - drug therapy (77) 77
rosuvastatin calcium - pharmacokinetics (76) 76
risk factors (75) 75
sulfonamides - pharmacology (75) 75
atorvastatin calcium (74) 74
fluorobenzenes - adverse effects (74) 74
pyrimidines - pharmacology (74) 74
rats (74) 74
pharmacology (71) 71
therapy (70) 70
drug therapy (69) 69
pyrimidines - adverse effects (68) 68
sulfonamides - adverse effects (68) 68
dyslipidemia (66) 66
fluorobenzenes - blood (66) 66
coronary-heart-disease (65) 65
pharmacogenetics (65) 65
sulfonamides - blood (64) 64
cross-over studies (63) 63
pyrimidines - blood (63) 63
nutritional and metabolic diseases (62) 62
organic anion transporters - metabolism (62) 62
pharmacology/toxicology (62) 62
statin (62) 62
administration, oral (61) 61
metabolism (61) 61
risk (59) 59
density-lipoprotein cholesterol (58) 58
organic anion transporters - genetics (58) 58
prevention (57) 57
coa reductase inhibitors (56) 56
drug therapy, combination (56) 56
drugs (56) 56
hepatic-uptake (56) 56
hydroxymethylglutaryl-coa reductase inhibitors - blood (55) 55
cardiovascular disease (54) 54
toxicology (54) 54
health aspects (53) 53
atherosclerosis (51) 51
solute carrier organic anion transporter family member 1b1 (51) 51
in-vitro (50) 50
internal medicine (50) 50
care and treatment (49) 49
expression (49) 49
rosuvastatin calcium - administration & dosage (49) 49
liver - metabolism (48) 48
cardiovascular diseases (47) 47
chemistry, analytical (47) 47
medicine, general & internal (47) 47
genotype (46) 46
medicine & public health (46) 46
drug-interactions (45) 45
dyslipidemias - drug therapy (45) 45
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (977) 977
Russian (6) 6
Japanese (4) 4
Chinese (2) 2
French (2) 2
Portuguese (2) 2
Spanish (2) 2
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Pharmaceutics, ISSN 1543-8384, 08/2012, Volume 9, Issue 8, pp. 2358 - 2363
The aims of this work were to study pharmacokinetics of randomly selected drugs in plasma and saliva samples in healthy human volunteers, and to introduce a... 
Salivary Excretion Classification System | effective permeability | pharmacokinetics | protein binding | bioequivalence | SimCYP | MEDICINE, RESEARCH & EXPERIMENTAL | RELATIVE BIOAVAILABILITY | PERMEABILITY | CLINICAL PHARMACOKINETICS | BIOLOGICAL FLUID | DRUGS | PHARMACOLOGY & PHARMACY | Quinolines - blood | Acetates - blood | Fluorobenzenes - pharmacokinetics | Hydrochlorothiazide - pharmacokinetics | Triazoles - blood | Piroxicam - blood | Azithromycin - blood | Humans | Losartan - blood | Saliva - secretion | Male | Naphthalenes - blood | Benzhydryl Compounds - blood | Fluorobenzenes - pharmacology | Quinolines - pharmacokinetics | Sulfonamides - blood | Azithromycin - pharmacokinetics | Tolterodine Tartrate | Female | Triazoles - pharmacokinetics | Naphthalenes - pharmacokinetics | Piroxicam - analogs & derivatives | Sitagliptin Phosphate | Hydrochlorothiazide - blood | Losartan - pharmacokinetics | Benzhydryl Compounds - pharmacokinetics | Metformin - blood | Cresols - blood | Phenylpropanolamine - blood | Metformin - pharmacokinetics | Rosuvastatin Calcium | Cloxacillin - pharmacokinetics | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Cinacalcet Hydrochloride | Cloxacillin - blood | Saliva - metabolism | Pyrazines - pharmacokinetics | Piroxicam - pharmacokinetics | Pyrimidines - pharmacokinetics | Cresols - pharmacokinetics | Anthraquinones - blood | Anthraquinones - pharmacokinetics | Phenylpropanolamine - pharmacokinetics | Pyrazines - blood | Acetates - pharmacokinetics
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 2004, Volume 94, Issue 9, pp. 1140 - 1146
Three-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors (statins) are first-line treatments for hypercholesterolemia. Although exceedingly well... 
CLARITHROMYCIN | INDUCED RHABDOMYOLYSIS | LOVASTATIN | CARDIAC & CARDIOVASCULAR SYSTEMS | CONCOMITANT USE | ERYTHROMYCIN | FATAL RHABDOMYOLYSIS | ITRACONAZOLE | ROSUVASTATIN | DRUG-INTERACTION | CYCLOSPORINE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Pyrroles - pharmacokinetics | Cytochrome P-450 Enzyme Inhibitors | Cytochrome P-450 Enzyme System - administration & dosage | Area Under Curve | Heptanoic Acids - pharmacokinetics | Humans | Middle Aged | Mibefradil - pharmacokinetics | Male | Protein Synthesis Inhibitors - administration & dosage | Verapamil - administration & dosage | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Antiprotozoal Agents - pharmacokinetics | Drug Interactions | Itraconazole - pharmacokinetics | Pyrroles - administration & dosage | Clarithromycin - pharmacokinetics | Mibefradil - administration & dosage | Clarithromycin - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Itraconazole - administration & dosage | Drug Therapy, Combination | Double-Blind Method | Simvastatin - administration & dosage | Verapamil - pharmacokinetics | Biomarkers - blood | Simvastatin - pharmacokinetics | Protein Synthesis Inhibitors - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Pravastatin - administration & dosage | Anticholesteremic Agents - administration & dosage | Adolescent | Antiprotozoal Agents - administration & dosage | Calcium Channel Blockers - administration & dosage | Creatine Kinase - drug effects | Calcium Channel Blockers - pharmacokinetics | Pravastatin - pharmacokinetics
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 08/2009, Volume 86, Issue 2, pp. 197 - 203
The ABCG2 c.421C>A single‐nucleotide polymorphism (SNP) was determined in 660 healthy Finnish volunteers, of whom 32 participated in a pharmacokinetic... 
BCRP GENE POLYMORPHISMS | ACID | HUMAN PLASMA | SLCO1B1 POLYMORPHISM | LACTONE FORMS | TRANSPORTER ABCG2 | PHARMACOLOGY & PHARMACY | INDUCED MYOPATHY | CANCER RESISTANCE PROTEIN | SINGLE NUCLEOTIDE POLYMORPHISMS | P-GLYCOPROTEIN | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Pyrroles - urine | Area Under Curve | Drug Resistance, Multiple | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Male | Reference Values | Fluorobenzenes - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | ATP-Binding Cassette Transporters - genetics | Sulfonamides - urine | Pyrroles - administration & dosage | Fluorobenzenes - urine | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | Neoplasm Proteins - genetics | European Continental Ancestry Group - genetics | Pyrimidines - administration & dosage | Rosuvastatin Calcium | Genotype | Linear Models | Pyrroles - blood | Sulfonamides - pharmacokinetics | Cross-Over Studies | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Heptanoic Acids - urine | Finland | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | Pyrimidines - urine | Heptanoic Acids - blood | Sulfonamides - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 04/2018, Volume 57, Issue 4, pp. 491 - 503
Background Ethnic variability in the pharmacokinetics of organic anion transporting polypeptide (OATP) 1B1 substrates has been observed, but its basis is... 
SLCO1B1 POLYMORPHISMS | COA REDUCTASE INHIBITORS | GENETIC POLYMORPHISMS | ABCG2 BCRP | PRAVASTATIN PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | ROSUVASTATIN PHARMACOKINETICS | POLYPEPTIDE 1B1 | DISPOSITION | SINGLE NUCLEOTIDE POLYMORPHISMS | ATORVASTATIN | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism | Humans | Asian Continental Ancestry Group - genetics | Carbamates - administration & dosage | Atorvastatin - administration & dosage | Healthy Volunteers | Neoplasm Proteins - metabolism | Quinolines - administration & dosage | Carbamates - pharmacokinetics | Rosuvastatin Calcium - administration & dosage | Liver-Specific Organic Anion Transporter 1 - genetics | Liver-Specific Organic Anion Transporter 1 - metabolism | Quinolines - pharmacokinetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Hypoglycemic Agents - administration & dosage | Computer Simulation | Pharmacogenomic Variants | Piperidines - pharmacokinetics | Neoplasm Proteins - genetics | European Continental Ancestry Group - genetics | Hypoglycemic Agents - pharmacokinetics | Piperidines - administration & dosage | Rosuvastatin Calcium - pharmacokinetics | Gene Frequency | ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics | Genotype | Phenotype | Pravastatin - administration & dosage | Models, Biological | Atorvastatin - pharmacokinetics | Pravastatin - pharmacokinetics
Journal Article
Pharmacogenetics and Genomics, ISSN 1744-6872, 12/2006, Volume 16, Issue 12, pp. 873 - 879
Journal Article
Xenobiotica, ISSN 0049-8254, 6/2013, Volume 43, Issue 6, pp. 498 - 508
1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and... 
P-glycoprotein | BCRP | transporters | Cytochrome P450 | OATP | dyslipidemia | diabetes | pharmacogenetics | Pharmacogenetics | Dyslipidemia | Transporters | Diabetes | POLYMORPHISM MARKEDLY AFFECTS | SLCO1B1 POLYMORPHISM | ATORVASTATIN | INHIBITION | PHARMACOKINETICS | FLUVASTATIN | PHARMACOLOGY & PHARMACY | TOXICOLOGY | SIMVASTATIN | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Simvastatin - adverse effects | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Male | Heptanoic Acids - adverse effects | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Young Adult | Drug Interactions | Piperidines - pharmacology | Oxadiazoles - pharmacology | Madin Darby Canine Kidney Cells | Pyrroles - adverse effects | Oxadiazoles - pharmacokinetics | Heptanoic Acids - pharmacology | Mesylates - blood | Troleandomycin - adverse effects | Rosuvastatin Calcium | Mesylates - adverse effects | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Simvastatin - analogs & derivatives | Sulfonamides - pharmacokinetics | Oxadiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Cytochrome P-450 CYP3A - metabolism | Adolescent | Atorvastatin | Pyrimidines - pharmacokinetics | Oxadiazoles - blood | Demography | Heptanoic Acids - pharmacokinetics | Mesylates - pharmacokinetics | Simvastatin - blood | Piperidines - blood | Troleandomycin - pharmacokinetics | Dose-Response Relationship, Drug | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Reference Standards | Adult | Female | Piperidines - pharmacokinetics | Troleandomycin - pharmacology | Fluorobenzenes - blood | Pyrroles - blood | Simvastatin - pharmacokinetics | Pyrroles - pharmacology | Animals | Cytochrome P-450 CYP3A Inhibitors | Mesylates - pharmacology | Piperidines - adverse effects | Dogs | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Heptanoic Acids - blood
Journal Article
Biopharmaceutics & Drug Disposition, ISSN 0142-2782, 07/2017, Volume 38, Issue 5, pp. 363 - 363
‘Physiologically based pharmacokinetic predictions of intestinal BCRP‐mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans’ by Soo... 
Periodical publishing | Rosuvastatin | Negotiation, mediation and arbitration | Analysis | Antilipemic agents | Libraries | Pharmacology | Internet | Pharmacokinetics | Intestine
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 06/2014, Volume 54, Issue 6, pp. 649 - 656
Statins are commonly used medications by HIV‐1 patients. Elvitegravir/cobicistat/emtricitabine/tenofovir DF is a single tablet regimen for the treatment of... 
pharmacokinetics | organic anion transporting polypeptide | breast cancer resistance protein | Stribild | statins | elvitegravir | HIV PROTEASE INHIBITORS | INTEGRASE | EMTRICITABINE | CO-FORMULATED ELVITEGRAVIR | INITIAL TREATMENT | TRANSPORT | EFAVIRENZ | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | INFECTION | TENOFOVIR | ATP Binding Cassette Transporter, Sub-Family G, Member 2 | Anti-HIV Agents - pharmacology | Fluorobenzenes - pharmacokinetics | Organic Anion Transporters, Sodium-Independent - antagonists & inhibitors | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Male | Neoplasm Proteins - antagonists & inhibitors | Carbamates - pharmacokinetics | Fluorobenzenes - pharmacology | Drug Interactions | Organic Anion Transporters, Sodium-Independent - metabolism | Quinolones - pharmacokinetics | Madin Darby Canine Kidney Cells | Solute Carrier Organic Anion Transporter Family Member 1B3 | Carbamates - pharmacology | Organic Anion Transporters - antagonists & inhibitors | Rosuvastatin Calcium | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Pyrimidines - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Cobicistat | ATP-Binding Cassette Transporters - antagonists & inhibitors | Thiazoles - blood | Cricetulus | Quinolones - pharmacology | Neoplasm Proteins - metabolism | Organic Anion Transporters - metabolism | Thiazoles - pharmacokinetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Quinolones - blood | Sulfonamides - blood | ATP-Binding Cassette Transporters - metabolism | Adult | Female | Anti-HIV Agents - blood | Drug Therapy, Combination | Fluorobenzenes - blood | CHO Cells | Carbamates - blood | Animals | Anti-HIV Agents - pharmacokinetics | Dogs | Thiazoles - pharmacology | Drug Combinations | Rosuvastatin | Dosage and administration | Pharmacokinetics | Analysis | Confidence intervals | Rodents
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 10/2017, Volume 57, Issue 10, pp. 1305 - 1314
Faldaprevir (FDV) is a potent, orally administered inhibitor of hepatitis C virus protease. It inhibits multiple cytochrome P‐450 enzymes and multiple membrane... 
faldaprevir | atorvastatin | rosuvastatin | drug–drug Interaction | COA REDUCTASE INHIBITOR | CHRONIC HEPATITIS-C | LIVER FIBROSIS | TRANSPLANT RECIPIENTS | INTERFERON-FREE | DRUG TRANSPORTERS | THERAPY | drug-drug Interaction | BI 201335 | GENOTYPE 1 INFECTION | PHARMACOLOGY & PHARMACY | PROTEASE INHIBITOR FALDAPREVIR | Atorvastatin Calcium - analogs & derivatives | Atorvastatin Calcium - blood | Pyrimidines - blood | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Middle Aged | Rosuvastatin Calcium - adverse effects | Male | Healthy Volunteers | Oligopeptides - adverse effects | Thiazoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Drug Interactions | Serine Proteinase Inhibitors - adverse effects | Adult | Female | Rosuvastatin Calcium - blood | Atorvastatin Calcium - adverse effects | Serine Proteinase Inhibitors - pharmacology | Atorvastatin Calcium - pharmacokinetics | Antiviral Agents - pharmacology | Rosuvastatin Calcium - pharmacokinetics | Cross-Over Studies | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antiviral Agents - adverse effects | Thiazoles - pharmacology | Oligopeptides - pharmacology | Rosuvastatin | Dosage and administration | Hepatitis C | Drug therapy | Pharmacokinetics | Analysis | Metabolites | Viruses | Cytochromes | Pharmacology | Hepatitis C virus | Drug dosages | Steady state
Journal Article
Pharmacogenomics Journal, ISSN 1470-269X, 02/2010, Volume 10, Issue 1, pp. 1 - 11
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are well established in the treatment of hypercholesterolaemia and the prevention of... 
SLCO1B1 | Statin | Transporter | Cholesterol | Myopathy | Polymorphism | REDUCTASE INHIBITORS | INTERINDIVIDUAL DIFFERENCES | myopathy | DRUG-INTERACTIONS | MULTIPLE-DOSE PRAVASTATIN | polymorphism | C SLC21A6 | LIPID-LOWERING EFFICACY | ANION TRANSPORTING POLYPEPTIDE | ABCB1 HAPLOTYPES | statin | transporter | GENETICS & HEREDITY | FUNCTIONAL-ANALYSIS | cholesterol | PHARMACOLOGY & PHARMACY | SINGLE NUCLEOTIDE POLYMORPHISMS | Haplotypes | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Heptanoic Acids - pharmacokinetics | Humans | Liver | Hepatocytes - metabolism | Hypercholesterolemia - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Organic Anion Transporters - genetics | Pharmacogenetics | Gene Frequency | Rosuvastatin Calcium | Simvastatin - pharmacokinetics | Anticholesteremic Agents - adverse effects | Sulfonamides - pharmacokinetics | Atorvastatin Calcium | Anticholesteremic Agents - pharmacokinetics | Asian Continental Ancestry Group | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Pyrimidines - pharmacokinetics | Polymorphism, Single Nucleotide | HeLa Cells | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Research | Health aspects | Coronary heart disease | Genetic polymorphisms | Statins | Risk factors
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 12/2007, Volume 82, Issue 6, pp. 726 - 733
Thirty‐two healthy volunteers with different SLCO1B1 genotypes ingested a 20 mg dose of atorvastatin and 10 mg dose of rosuvastatin with a washout period of 1... 
COA REDUCTASE INHIBITOR | ANION TRANSPORTING POLYPEPTIDE | PLASMA-CONCENTRATIONS | PHARMACOLOGY & PHARMACY | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | HEALTHY-VOLUNTEERS | INDUCED MYOPATHY | OATP-C SLC21A6 | SINGLE NUCLEOTIDE POLYMORPHISMS | CLINICAL-RELEVANCE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Fluorobenzenes - pharmacokinetics | Prospective Studies | Pyrroles - pharmacokinetics | Area Under Curve | Pyrimidines - blood | Heptanoic Acids - pharmacokinetics | Humans | Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood | Male | Reference Values | Fluorobenzenes - administration & dosage | Organic Anion Transporters - metabolism | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Sulfonamides - blood | Organic Anion Transporters - genetics | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Adult | Female | Fluorobenzenes - blood | European Continental Ancestry Group - genetics | Administration, Oral | Pyrimidines - administration & dosage | Liver - metabolism | Rosuvastatin Calcium | Genotype | Pyrroles - blood | Sulfonamides - pharmacokinetics | Polymorphism, Genetic | Atorvastatin Calcium | Pyrimidines - pharmacokinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Heptanoic Acids - blood | Sulfonamides - administration & dosage
Journal Article